- HCC-78
- HDLM-2
- DOHH-2
- L-540
- MX-1
- NALM-6
- NB-4
- CAL-51
- SNB-19
- KYSE-520
- MKN-45
- BA/F3
- MS-5
- HCEC-B4G12
- NK-92
- PA-TU-8988S
- MONO-MAC-1
- PA-TU-8902
- Human Microglia
- Human Hepatic Stellate Cells
- Human Skeletal Muscle Cells (DMD)
- Human Schwann Cells
- Human Oral Keratinocytes (HOK)
- Human Cardiomyocytes
- Human Small Intestinal Epithelial Cells
- Human Colonic Epithelial Cells
- Human Intestinal Fibroblasts
- Primary Human Large Intestine Microvascular Endothelial Cells
- Human Small Intestinal Microvascular Endothelial Cells
- Human Retinal Pigment Epithelial Cells
- Human Hepatocytes
- Cynomolgus Monkey Lung Microvascular Endothelial Cells
- Cynomolgus Monkey Vein Endothelial Cells
- C57BL/6 Mouse Primary Mammary Epithelial Cells
- C57BL/6 Mouse Vein Endothelial Cells
- Rat Primary Kidney Epithelial Cells
- Rat Gingival Epithelial Cells
- Rabbit Lung Endothelial Cells
Our Promise to You
Guaranteed product quality, expert customer support
ONLINE INQUIRY
HP2 Heps 10 Human Pooled Primary Hepatocytes
Cat.No.: CSC-C4108X
Species: Human
Source: Liver
Cell Type: Hepatocyte
- Specification
- Background
- Scientific Data
- Q & A
- Customer Review
Cell Features:
Each donor's hepatocytes have been cryopreserved ONCE immediately after isolation and purification.
Pools of 10 or 20 donors are available. Each donor is represented by a statistically significant number of cells relative to the pool.
There is extensive quality control providing characterization of viability and enzyme activity from both individual donors and the total pool.
Creative Bioarray guarantees performance and quality.
Donor information is available.
Human hepatocytes are the primary parenchymal cells in the human liver, with an adult liver containing over 2.5 billion hepatocytes and more than 500,000 liver lobules composed of these cells. They are responsible for a multitude of metabolic, detoxification, and synthetic functions, participating in many critical physiological processes and playing a pivotal role in maintaining hepatic homeostasis. Given their crucial role in detoxification and metabolism, primary hepatocytes are widely used as in vitro models to study drug metabolism pathways and pharmacokinetics in the liver. These cells are regarded as the gold standard in related studies and are ideal for clinical hepatocyte transplantation and bioartificial liver development.
However, hepatocytes derived from single donors present certain limitations. The metabolic characteristics of hepatocytes from an individual donor may not comprehensively represent the broader population due to significant inter-individual variability in the activity and expression levels of drug-metabolizing enzymes. This variability can lead to inaccurate predictions of drug responses. The use of pooled donor primary hepatocytes can address this limitation. Pooled hepatocytes better reflect the metabolic capacity of the general population, thereby reducing experimental bias caused by genetic differences among individuals. This approach provides a more comprehensive metabolic profile and drug response pattern. Additionally, since the liver is composed of various cell types, pooled hepatocytes can more accurately simulate the complex in vivo hepatic environment. Furthermore, in the development of bioartificial organs, the use of pooled hepatocytes can enhance the functionality and adaptability of these organs. Thus, selecting pooled hepatocytes based on specific research needs can facilitate more effective and accurate studies.
Fig. 1. Morphology of pooled cryopreserved human hepatocytes (Li A. P., 2015).
Determination of Metabolites in Plasma of Volunteers and Pooled Hepatocytes Cultures
Amiodarone (ANT) is a first-generation antiarrhythmic and anticholinergic drug that has been widely used in clinical practice. Recent studies have found that this medication is also highly effective in terminating atrial fibrillation. However, it has not been included in clinical guidelines, and data on its metabolism in the human body are lacking. Therefore, Giebułtowicz J, et al. analyzes the metabolic profile of intravenously injected ANT in plasma and pooled human hepatocytes using liquid chromatography-tandem mass spectrometry.
By analyzing the chromatograms of plasma extracted from volunteers, 15 potential metabolites of ANT were identified. Most of the metabolites found in volunteer plasma were also detected in in vitro assays with pooled human hepatocytes. These metabolites include Phase I products such as M1, M2, and metabolites MW295 and MW299, as well as Phase II products like methylated and glucuronidated compounds M6, MW485, and MW487b. Some metabolites are conjugated with glucuronic acid (e.g., M3, M4, M5, M7, M8, MW351, MW475) or sulfuric acid (MW361). The main metabolic pathways for the compound ANT are illustrated in Figure 1, showing transformations such as cleavage, hydroxylation, and conjugation. Some specific metabolites, like compounds B and C, were found under certain conditions but did not meet criteria for significant metabolite selection in in vivo studies. The study showcases the intricate pathways of ANT metabolism involving multiple transformations and conjugations.
Fig. 1. The main pathways of ANT metabolism and putative structure of Phase I and Phase II metabolites (Giebułtowicz J, Korytowska N, et al., 2020).
Gene-Level Analysis of Pooled Human Hepatocytes Exposed to Thioacetamide
The employment of pooled hepatocyte cultures in in vitro experiments to study the metabolism, toxicity, and drug interactions of chemicals can reduce variability. Toxicogenomics aids in understanding how gene expression patterns and subsequent affected pathways characterize physiological responses to drugs and toxins. However, the utility or applicability of pooled human hepatocytes in predicting hepatotoxicity remains unclear. Therefore, the objective of this study is to evaluate the response of pooled human hepatocytes to thioacetamide exposure. Goel H, et al. examined RNA-seq data from five individual lots of pooled primary human hepatocytes, as well as a combined lot, following thioacetamide exposure, and analyzed the homogeneity and variability of these pooled hepatocyte cultures using various toxicogenomic approaches.
Through RNA sequencing data analysis, the researchers identified gene expression responses induced by harmful substance exposure. The number of genes in different lots of pooled hepatocytes varied significantly, ranging from 2,241 to 3,521. Additionally, there was a substantial overlap of genes among the different lots, with 816 common differentially expressed genes, indicating similarity in genes affected by thioacetamide (Fig. 2). Studying these genes can help focus on their potential roles in liver function and damage. Notably, the downregulated genes CYP26B1 and CYP26A1 are responsible for the clearance of retinoic acid in the liver. When thioacetamide was administered to rats, elevated retinoic acid levels and reduced activity of related enzymes were observed. The upregulated genes C2CD4B and C2CD4A primarily participate in the regulation of inflammatory responses. SPP1 and THRSP were also among the top 10 differentially expressed genes, with SPP1 being an important biomarker for fibrosis and FGF21 playing a crucial role in lipid metabolism and reducing hepatocyte damage. Furthermore, several genes like SPP1 and THRSP are associated with liver injury.
Fig. 2. Venn diagram depicting the common differentially expressed genes across different lots of in vitro pooled human hepatocytes exposed to thioacetamide treatment (Goel H, Printz RL, et al., 2024).
Ask a Question
Write your own review